INS and heart failure: Although specifically studying people with type 2 diabetes, we considered that if empagliflozin treatment enhanced vascular insulin sensitivity, such an action might also at least partially explain the beneficial cardiovascular and renal effects of this drug class in nondiabetic patients with cardiovascular disease (CVD), heart failure (13), or chronic renal disease (27), each condition itself being associated with insulin resistance.